

State of Oklahoma SoonerCare

Yescarta[®] (Axicabtagene Ciloleucel) Prior Authorization Form

Date of Birth:	Member ID#:
Drug Information	
PCS code:) Start Dat	te:
Billing Provider Information	
Provider Na	ame:
Provider Phone: Provider Fax:	
Prescriber Information	
Prescriber Name:	
Prescriber Fax:	Specialty:
Criteria	
For Authorization: 1. Please include the most recent office visit note or clinical summary from the hospital to support your request. Is this information attached? Yes No 2. Is the health care facility on the certified list to administer CAR T-cells? Yes No 3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes No 4. Will the health care facility comply with the Yescarta® REMS Program requirements? Yes No 5. Please indicate the diagnosis and information: □ Large B-cell lymphoma A. Does diagnosis include diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, DLBCL arising from follicular lymphoma (FL), or FL? Yes No B. If diagnosis includes DLBCL, high grade B-cell lymphoma, or DLBCL arising from FL, does member have primary central nervous system lymphoma? Yes No C. Is disease status refractory or relapsed? Yes No i. If refractory or relapsed disease, has member received 2 or more lines of therapy? Yes No 1. If yes, please provide additional information regarding previous therapies member has tried and failed: ii. If refractory or relapsed disease, has member received 1 previous line therapy? Yes No 2. Did relapse occur within 12 months of first-line chemotherapy? Yes No I f diagnosis is not listed above, please indicate diagnosis:	
Additional Information:	
Prescriber Signature: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my	
	Billing Provider Information Provider Name: Prescriber Information Prescriber Name: Prescriber Fax: Criteria trecent office visit note or clinical summant tached? Yes No yon the certified list to administer CAR T-yot trained in the management of cytokine responsis and information: homa sinclude diffuse large B-cell lymphoma (Elicular lymphoma (FL), or FL? Yes No cludes DLBCL, high grade B-cell lymphoma? Yes us refractory or relapsed? Yes No or relapsed disease, has member received ease provide additional information regard d: or relapsed disease, has member received the refractory to first-line chemotherapy? Yes ease occur within 12 months of first-line chemotherial received the refractory to first-line chemotherapy? Yes expressed the please indicate diagnosis.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 97 8/25/2022

Failure to complete this form in full and attach requested clinical notes will result in processing delays.